US exempts select Indian specialty drugs from 100% tariff
In short
The United States has exempted some specialty drugs and ingredients from India from a new 100% pharma tariff. The report says this covers certain medicines for urgent health needs, including rare diseases and nuclear medicines, starting September 29 for eligible goods.
This matters to Indian drug makers because some exports may avoid the tariff, while generics are still not affected by it. The reporting does not say which companies will benefit or how many products qualify.
What the reporting says
The United States has exempted certain Indian specialty pharmaceuticals and ingredients from the newly imposed 100% pharma tariff, according to a publisher summary. The reported exemption covers products tied to urgent health needs, including rare-disease and nuclear medicines, while generics are not subject to the tariff. The source says eligible imports can seek Commerce approval, but it does not state which specific companies or products were approved.
Why it matters
The reported US move gives a tariff exemption for select Indian specialty pharmaceuticals and ingredients from the new 100% pharma tariff. The summary says the carve-out applies from September 29 for eligible goods tied to urgent health needs, including rare-disease and nuclear medicines, while generics remain outside the tariff. The available reporting does not identify specific companies or exact product lists.